Drug intelligence / Profile preview

NT-0300

Development stage: Preclinical
Lead developer: NeuBase Therapeutics
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics

Overview

NT-0300 is a preclinical-stage therapeutic developed by NeuBase Therapeutics targeting the mutated KRAS gene, specifically designed as an inhibitor of KRAS G12D and G12V mutations, which are common oncogenic drivers in various cancers. It leverages NeuBase's PATrOL platform, likely involving peptide-nucleic acid antisense oligonucleotides (PNAs) for precise genetic modulation to inhibit mutant KRAS function. The program aims to address unmet needs in KRAS-mutant neoplasms, including solid tumors.[1][3][13]

Targets

Kirsten rat sarcoma viral oncogene homolog mRNA

Beyond the preview

Go deeper on NT-0300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NT-0300.

Explore the full profile